Compare Hims and Hers Health Inc (HIMS) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Hims and Hers Health Inc trades at $28.34 (market cap $6.89B), while Vanguard Intermediate Term Corporate Bond ETF trades at $78.79 (market cap $72.20B). The key difference: Vanguard Intermediate Term Corporate Bond ETF is far larger — about 10.5× Hims and Hers Health Inc's market cap, and Hims and Hers Health Inc is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Vanguard Intermediate Term Corporate Bond ETF for 61 Days on average.
| HIMS | VCIT | |
|---|---|---|
Market Cap | $6.89B | $72.20B |
Volume | 5,446,628 | 14,162,206 |
Sector | Health | Fixed Income |
52-Week High | $62.76 | $84.82 |
52-Week Low | $14.52 | $77.98 |
Typical Hold Time | 21 Days | 61 Days |
Enterprise Value | $7.60B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $29.54, up 0.24% on the day, with a bullish technical signal from moving averages but mixed earnings performance. Revenue grew to $2.35 billion in 2025, yet the company posted a net loss of $142 million in 2026, reflecting profitability challenges. High valuation ratios like a P/E of 57.14 and negative ROE of -32.03% indicate premium pricing despite weak earnings. Recent news highlights multiple securities class action lawsuits filed in October 2026, creating legal overhangs.
The stock faces headwinds from profitability struggles and legal risks, but analyst consensus remains a Buy with a $32.17 price target, suggesting modest upside. Investment appeal hinges on resolving operational inefficiencies and legal issues to align valuation with fundamentals, while current sentiment is cautious due to recent earnings misses and regulatory scrutiny.
VCIT trades at $78.27 with minimal daily movement (+0.04%). Technical indicators show a bearish trend with strong selling pressure in moving averages, though oscillators are neutral. The ETF offers a 4.8% yield with a 6-year duration, positioning it as a balanced income option among investment-grade corporate bond ETFs. Recent institutional buying includes Engineers Gate Manager LP's $1.27 million purchase in September 2026.
VCIT presents a compelling risk-return profile for income-focused investors seeking corporate bond exposure. The fund's low 0.03% expense ratio and higher yield compared to treasury alternatives provide value, though interest rate sensitivity and market volatility remain key risks. Analyst sentiment is generally positive given its competitive positioning in the fixed income ETF space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
